2013 MAR 18 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Current study results on Immune System Diseases and Conditions have been published. According to news originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "The immunogenicity of pneumococcal conjugate vaccine (PCV) has not been evaluated in HIV-infected infants following the first and second PCV-doses. We studied antibody kinetics of serotypes included in 7-valent PCV in HIV-infected and HIV-uninfected infants prior to and following each of three PCV-doses."
Our news journalists obtained a quote from the research from the Henry M. Jackson Foundation for the Advancement of Military Medicine, "HIV-uninfected infants born to HIV-uninfected (HUU) and HIV-infected mothers (HEU); and perinatal HIV-infected children with CD4+ <25% randomized to initiate antiretroviral treatment (ART) when clinically and/or immunologically indicated (ART-) or immediately (ART+) were enrolled. Vaccination occurred at approximately 7.4, 11.5 and 15.5 weeks of age. Serotype-specific antibody was measured by ELISA following each PCV-dose and opsonophagocytic activity (OPA) to three serotypes following the second and third doses. Pre-vaccination, antibody geometric mean concentrations (GMCs) were higher in HUU compared to HIV-exposed groups for most serotypes. GMCs and proportion of infants with antibody >= 0.35 mu g/ml were similar in HUU compared to other groups following the second PCV-dose. In all groups, GMCs were greater following the third compared to post-second dose; and a higher proportion within each group had antibody >= 0.35 mu g/ml to 6B and 23F. OPA GMTs increased after the third compared to post-second dose for studied-serotypes; as did the proportion with OPA >= 8 to 23F. A two-dose primary-series of PCV probably confers similar protection against invasive pneumococcal disease in HIV-infected compared to HUU children."
According to the news editors, the research concluded: "The inferior response to serotypes 6B and 23F, and lower GMCs and OPA GMTs, following two compared to after three PCV-doses may have implications in the prevention of pneumococcal disease in high-burden countries."
For more information on this research see: Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine, 2013;31(5):777-783. Vaccine can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)
The news correspondents report that additional information may be obtained from S.A. Madhi, Henry Jackson Fdn, Div AIDS HJF DAIDS, Bethesda, MD, United States (see also Immune System Diseases and Conditions).
Keywords for this news article include: Antibodies, Bethesda, Maryland, HIV/AIDS, Virology, Immunology, RNA Viruses, Vaccination, Immunization, Retroviridae, United States, Blood Proteins, HIV Infections, Immunoglobulins, Conjugate Vaccines, Pediatric Vaccines, Synthetic Vaccines, Vertebrate Viruses, Biological Products, Risk and Prevention, Pneumococcal Disease
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC